Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Arch Dermatol Res. 2016 Sep;308(7):461-71. doi: 10.1007/s00403-016-1647-6. Epub 2016 Apr 30.

Current and future direction in the management of scleroderma.

Author information

1
The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer, NY, 12144, USA.
2
Division of Rheumatology, Steffens Scleroderma Center, Albany Medical College, Albany, NY, USA.
3
The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer, NY, 12144, USA. shaker.mousa@acphs.edu.

Abstract

Scleroderma is a heterogeneous disease with a complex etiology. As more information is gained about the underlying mechanisms and the improved classifications of scleroderma subtypes, treatments can be better personalized. Improving scleroderma patients' early diagnosis before end organ manifestations occur should improve clinical trial design and outcomes. Two recently FDA-approved antifibrotics for idiopathic pulmonary fibrosis may be effective treatments in patients with pulmonary fibrosis secondary to scleroderma after further investigation. The potential impact of Nanobiotechnology in improving the efficacy and safety of existing antifibrotics and immunomodulators might present an exciting new approach in the management of scleroderma.

KEYWORDS:

Autoimmunity; Diagnosis; Fibrosis; Immunosuppressant; Nano targeting; Scleroderma; Vasculopathy

PMID:
27139430
DOI:
10.1007/s00403-016-1647-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center